Premium Reports
Contact KLAS
 Download Report Brief  Download Full Report    Zoom in charts

Preferences

   Bookmark

Related Series

Radiology Dose Monitoring Solutions 2014
|
2014

 End chart zoom
Are All Dose Monitoring Solutions Created Equal? Early Trends in an Emerging Market Are All Dose Monitoring Solutions Created Equal? Early Trends in an Emerging Market
* A page refresh may be necessary to see the updated image

Are All Dose Monitoring Solutions Created Equal? Early Trends in an Emerging Market

author - Monique Rasband
Author
Monique Rasband
author - Emily Paxman
Author
Emily Paxman
 
June 9, 2015 | Read Time: 2  minutes

Early adopters of dose monitoring solutions have found that the tools make a difference in quality improvement, protocol optimization, and patient safety. While this emerging market is still in the early stages—most vendors outside of Bayer have a small install base—KLAS data includes early indicators that vendors differ in their ability to help in those three areas.

1. BAYER HEALTHCARE IS THE CLEAR LEADER IN AN EMERGING DOSE MARKET

Bayer is by far the most widely adopted dose system on the market—no other system’s install base is close. Paired with strong tools that trigger warnings when thresholds are crossed, the level of detail available through reporting and benchmarking improves overall quality. Providers have achieved a high degree of connectivity due to Bayer’s neutral architecture. A few providers reported that issues with installation personnel and inadequate training prevented them from fully leveraging all of Bayer’s functionality.

vendor site validation across the enterprise

2. PROVIDERS ENTHUSIASTIC ABOUT UP-AND-COMER PACSHEALTH

Early data indicates that PACSHealth improves quality by offering accurate tools that enable simple data mining and extensive protocol optimization. Providers have successfully connected the solution to various vendors’ equipment across all major imaging modalities. Looking forward, providers are confident in their own plans to expand its use due to the high level of engagement and guidance from their vendor that help with the training, installation, and planning.

an early look at market performance

3. GE HEALTHCARE SLOW TO DELIVER NEW FUNCTIONALITY

Despite strong automatic data importation, providers reported functionality gaps around customization, setting parameters, monitoring based on dose-index volumes, and nuclear medicine. Additionally, comparing organizations and doing external reporting to the ACR Dose Index Registry are challenges for some, despite success using internal benchmarking to improve patient safety. Functionality gaps have also been reported by some providers who have connected the dose product to a non-GE modality.

overall functionality

"I don't know how much we have invested, but I think that it was worth it and will be worth it in the future." -Radiology Director

4. PROVIDERS ARE EXPANDING USE CASES

Moving forward, quality improvement, protocol optimization, and patient safety will be the primary use cases for most providers’ dose monitoring solutions. This represents an important market shift. In order to remain competitive, vendors must improve their solutions to help providers improve in these areas. Today, GE has the most use cases per customer, in spite of functionality gaps. This is the result of GE’s efforts to help providers use the dose solution with existing GE tools.

primary use cases for dose monitoring

author - Natalie Jamison
Designer
Natalie Jamison
author - Robert Ellis
Project Manager
Robert Ellis
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.

​